Irbesartan, 99%, a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist

Name: Irbesartan, 99%, a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist | 138402-11-6
Brand: J&K Chemical
SKU: JK562762_5_G
Price: 329.0 USD
Availability: InStock

Cat. No JK562762_5_G

Vendor: J&K Chemical

Product Information

Product Name

Irbesartan, 99%, a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist

Brand Name

J&K

Product Number

562762

CAS

138402-11-6

Molecular Formula

C25H28N6O

Molecular Weight

428.53

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

Synonyms

2-Butyl-3-2′-(2H-tetrazol-5-yl)1,1′-biphenyl-4-ylmethyl-1,3-diazaspiro4.4non-1-en-4-one
Avapro
BMS-186295
SR-47436

PubChem CID

3749

IUPAC Name

2-butyl-3-4-2-(2H-tetrazol-5-yl)phenylphenylmethyl-1,3-diazaspiro4.4non-1-en-4-one

InChI Key

YOSHYTLCDANDAN-UHFFFAOYSA-N

SMILES

CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5

Properties

Melting Point

180-181

Safety Information

Precautionary Statement

P262

Storage Condition

Freezer -20℃

References Data Source From Pubchem

Zilebesiran: an RNA interference agent—its need and potential to transform hypertension treatment

Publication Name: The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology

Publication Date: 2026-03-01

DOI: 10.1186/s43044-026-00724-9

Long-term risk of dementia with angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors in hypertensive patients: A 15-year follow-up using the 45 and Up Study

Publication Name: GeroScience

Publication Date: 2026-02-27

DOI: 10.1007/s11357-026-02173-3

RAS blockade in chronic kidney disease: Current evidence and future directions

Publication Name: Naunyn-Schmiedeberg's Archives of Pharmacology

Publication Date: 2026-02-26

DOI: 10.1007/s00210-026-05140-z

Prevalence of substances with OATP1B1 inhibitory properties in individual case safety reports of suspected statin-associated myopathy – an analysis of Swiss pharmacovigilance data

Publication Name: European Journal of Clinical Pharmacology

Publication Date: 2026-02-24

DOI: 10.1007/s00228-025-03968-7

A Perspective on Quaternary Treatments for Micropollutant Elimination in Urban Wastewater Treatment Plants

Publication Name: Earth Systems and Environment

Publication Date: 2026-02-24

DOI: 10.1007/s41748-026-01086-7

Irbesartan, 99%, a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist

Product Information

General Information

Properties

Safety Information

References Data Source From Pubchem

Zilebesiran: an RNA interference agent—its need and potential to transform hypertension treatment

Long-term risk of dementia with angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors in hypertensive patients: A 15-year follow-up using the 45 and Up Study

RAS blockade in chronic kidney disease: Current evidence and future directions

Prevalence of substances with OATP1B1 inhibitory properties in individual case safety reports of suspected statin-associated myopathy – an analysis of Swiss pharmacovigilance data

A Perspective on Quaternary Treatments for Micropollutant Elimination in Urban Wastewater Treatment Plants